Abnormal Uterine Bleeding (AUB) 2

Total Page:16

File Type:pdf, Size:1020Kb

Abnormal Uterine Bleeding (AUB) 2 ·:{iC0Fp'16 ACOFP 53rd Annual Convention & Scientific Seminars Dysfunctional Uterine Bleeding Michele Tartaglia, DO 3/17/2016 Michele Tartaglia, DO, FACOOG, CS Assistant Professor and Residency Program Director Rowan University School of Osteopathic Medicine Department of Obstetrics & Gynecology Objectives 1. Define normal and abnormal uterine bleeding (AUB) 2. Describe a patterns based approach to AUB 3. Understand the diagnostic modalities commonly used in the workup of AUB 4. Describe the different options for both the medical and surgical management of AUB Financial Disclosure No financial disclosures to report 1 3/17/2016 Misc. Disclosure Entire talk based on one article with some evidence based updating and commentary from me I’m not the only author of this talk!!! JABFM Article • Authors = 2 family docs and 2 gynecologists • MEDLINE search for algorithms for clinical management AUB • Also examined care of 100 random women in university gyn clinic • Then honed own clinically based algorithm • Noticed that gyns usually immediately group all AUB patients into one of 4 groups 2 3/17/2016 JABFM Article 1. Severe acute bleeding 2. Irregular bleeding 3. Menorrhagia 4. Abnormal bleeding associated with contraceptive use • Oral contraceptives • Depo-medroxyprogesterone • Intrauterine devices Normal Uterine Bleeding Normal interval is 21-35 days Normal duration is 1-7 days Gyn textbook answer – two to eight days Normal amount is less than 1 pad or tampon every 3 hours 3 3/17/2016 Severe Acute Bleeding Severe Acute Bleeding Bleeding that requires more than one pad/tampon per hour AND/OR Vital signs indicating hypovolemia Severe Acute Bleeding Common causes: Adolescents – coagulopathy (vonWillebrand disease, leukemia) Fibroids – especially submucosal People on anticoagulants Obesity – anovulatory cycles and adenomyosis Trauma Tailor your lab workup to the individual patient Ultrasound NOT as helpful in the adolescent 4 3/17/2016 Severe Acute Bleeding “Cycle Provera” – consider starting high dose (10mg BID-TID) with taper then standard dose (10mg qHS x 10-21 days) next two cycles Severe Acute Bleeding Alternative medical therapies Tranexamic acid Antifibrinolytic agent Not studied for acute AUB IV and PO options Foley catheter placed into uterus Tamponade 26F with 30mL saline – case reports proving efficacy Desmopressin or recombinant Factor VIII in patients with vonWillebrand disease 5 3/17/2016 Severe Acute Bleeding Surgical options D&C Endometrial Ablation Uterine artery embolization Hysterectomy Severe Acute Bleeding Summary Irregular Bleeding 6 3/17/2016 Irregular Bleeding Includes: Metrorrhagia Menometrorrhagia Oligomenorrhea Prolonged bleeding Intermenstrual bleeding Any other irregular pattern Irregular Bleeding Not every patient needs evaluation! Adolescent in the first 2 yr after menarche immaturity HPO axis However may request intervention Perimenopausal patient Some shortening or lengthening of the cycle is expected Repeated cycles outside the normal range or other AUB requires endometrial biopsy Reproductive age woman Some spotting just before, just after, or at ovulation can be normal However, ANY midcycle bleeding in an older patient should be worked up HCG, TSH, prolactin 7 3/17/2016 Endometrial Biopsy Paper: Age >35 with irregular bleeding REQUIRE biopsy ACOG >45yo as first line test <45yo if hx unopposed estrogen (PCOS, obesity), failed medical management, persistent AUB Sensitivity of EMB in studies that use hysterectomy: 68%, used D&C: 78% Samples an average of 4% of the endometrium Still a good test – just consider further eval if no response to therapy in the face of a normal EMB Transvaginal Ultrasound Identify polyps, fibroids, very thick EMS EMS < 5mm = VERY low likelihood of endometrial hyperplasia or carcinoma Large meta-analysis: intrauterine abnormalities found in 46.6% of women with AUB Try to schedule day 4-6 of cycle (EMS thin) Proliferative phase EMS usually 4-8mm Secretory phase EMS usually 8-14mm Saline infusion sonohysterography even more accurate 8 3/17/2016 Systemic Causes Chronic endometritis – treat w doxy 100mg BID x 10d Medications – eg. TCAs, corticosteriods, antipsychotics Systemic disease – liver or kidney failure, thyroid d/o Hyperandrogenic syndromes PCOS Congenital adrenal hyperplasia Androgen secreting tumors Hyperprolactinemia 9 3/17/2016 Menorrhagia Menorrhagia Heavy but regular, cyclic bleeding Blood loss greater than 80mL per cycle or patient perception of very heavy bleeding Large clots Iron deficiency anemia If the bleeding lasts > 12 days (arbitrary set by authors) follow irregular bleeding algorithm Menorrhagia Up to 20% of women have an underlying bleeding disorder – MUST SCREEN YES answer to any of the following is a +screen HMB since menarche One of the following: PP hemorrhage Surgery related bleeding Bleeding assoc w dental work Two or more of the following: Bruising 1-2x a month Epistaxis 1-2x a month Frequent gum bleeding Family hx bleeding symptoms 10 3/17/2016 11 3/17/2016 Tranexamic Acid Oral antifibrinolytic FDA approved for treatment of HMB of greater than 80mL per cycle Few case reports of arterial and venous thrombosis NO REPORTS of VTE Contraindicated in those w hx or high risk VTE No data on use with COCs - contraindicated Reduces blood loss by 40-65% TID dosing only on days of heaviest bleeding – max 5 days 12 3/17/2016 AUB from Hormonal Contraception 13 3/17/2016 References • Ely JW, Kennedy CM, Clark EC, Bowdler NC. Abnormal Uterine Bleeding: a management algorithm. J Am Board Fam Med. 2006. 19(6):590-602. • ACOG Practice Bulletin Number 557. Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. April 2013 (Reaffirmed 2015). • ACOG Practice Bulletin Number 128. Diagnosis of Abnormal Uterine Bleeding in Reproductive Aged Women. July 2012 (Reaffirmed 2014). • ACOG Practice Bulletin Number 136. Management of Abnormal Uterine Bleeding Associated with Ovulatory Dysfunction. July 2013 (Reaffirmed 2015). • Curtis M, Overholt S, Hopkins M. Glass’ Office Gynecology. 6th Edition. Lippincott Williams & Wilkins. 2006. • Lysteda (package insert). Parsippany, NJ: Ferring Pharmaceuticals Inc.; Rev 10/2013. • Kost A, Pitney C. Tranexamic Acid (Lysteda) for Cyclic Heavy Menstrual Bleeding. American Family Physician. Volume 84, Number 8. October 15, 2011. Enjoy Puerto Rico!!!! Michele Tartaglia, DO, FACOOG, CS [email protected] 14.
Recommended publications
  • The Male Reproductive System
    Management of Men’s Reproductive 3 Health Problems Men’s Reproductive Health Curriculum Management of Men’s Reproductive 3 Health Problems © 2003 EngenderHealth. All rights reserved. 440 Ninth Avenue New York, NY 10001 U.S.A. Telephone: 212-561-8000 Fax: 212-561-8067 e-mail: [email protected] www.engenderhealth.org This publication was made possible, in part, through support provided by the Office of Population, U.S. Agency for International Development (USAID), under the terms of cooperative agreement HRN-A-00-98-00042-00. The opinions expressed herein are those of the publisher and do not necessarily reflect the views of USAID. Cover design: Virginia Taddoni ISBN 1-885063-45-8 Printed in the United States of America. Printed on recycled paper. Library of Congress Cataloging-in-Publication Data Men’s reproductive health curriculum : management of men’s reproductive health problems. p. ; cm. Companion v. to: Introduction to men’s reproductive health services, and: Counseling and communicating with men. Includes bibliographical references. ISBN 1-885063-45-8 1. Andrology. 2. Human reproduction. 3. Generative organs, Male--Diseases--Treatment. I. EngenderHealth (Firm) II. Counseling and communicating with men. III. Title: Introduction to men’s reproductive health services. [DNLM: 1. Genital Diseases, Male. 2. Physical Examination--methods. 3. Reproductive Health Services. WJ 700 M5483 2003] QP253.M465 2003 616.6’5--dc22 2003063056 Contents Acknowledgments v Introduction vii 1 Disorders of the Male Reproductive System 1.1 The Male
    [Show full text]
  • Prolactin Level in Women with Abnormal Uterine Bleeding Visiting Department of Obstetrics and Gynecology in a University Teaching Hospital in Ajman, UAE
    Prolactin level in women with Abnormal Uterine Bleeding visiting Department of Obstetrics and Gynecology in a University teaching hospital in Ajman, UAE Jayakumary Muttappallymyalil1*, Jayadevan Sreedharan2, Mawahib Abd Salman Al Biate3, Kasturi Mummigatti3, Nisha Shantakumari4 1Department of Community Medicine, 2Statistical Support Facility, CABRI, 4Department of Physiology, Gulf Medical University, Ajman, UAE 3Department of OBG, GMC Hospital, Ajman, UAE *Presenting Author ABSTRACT Objective: This study was conducted among women in the reproductive age group with abnormal uterine bleeding (AUB) to determine the pattern of prolactin level. Materials and Methods: In this study, a total of 400 women in the reproductive age group with AUB attending GMC Hospital were recruited and their prolactin levels were evaluated. Age, marital status, reproductive health history and details of AUB were noted. SPSS version 21 was used for data analysis. Descriptive statistics was performed to describe the population, and inferential statistics such as Chi-square test was performed to find the association between dependent and independent variables. Results: Out of 400 women, 351 (87.8%) were married, 103 (25.8%) were in the age group 25 years or below, 213 (53.3%) were between 26-35 years and 84 (21.0%) were above 35 years. Mean age was 30.3 years with a standard deviation 6.7. The prolactin level ranged between 15.34 mIU/l and 2800 mIU/l. The mean and SD observed were 310 mIU/l and 290 mIU/l respectively. The prolactin level was high among AUB patients with inter-menstrual bleeding compared to other groups. Additionally, the level was high among women with age greater than 25 years compared to those with age less than or equal to 25 years.
    [Show full text]
  • Endometriosis for Dummies.Pdf
    01_050470 ffirs.qxp 9/26/06 7:36 AM Page i Endometriosis FOR DUMmIES‰ by Joseph W. Krotec, MD Former Director of Endoscopic Surgery at Cooper Institute for Reproductive Hormonal Disorders and Sharon Perkins, RN Coauthor of Osteoporosis For Dummies 01_050470 ffirs.qxp 9/26/06 7:36 AM Page ii Endometriosis For Dummies® Published by Wiley Publishing, Inc. 111 River St. Hoboken, NJ 07030-5774 www.wiley.com Copyright © 2007 by Wiley Publishing, Inc., Indianapolis, Indiana Published by Wiley Publishing, Inc., Indianapolis, Indiana Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permit- ted under Sections 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-646-8600. Requests to the Publisher for permission should be addressed to the Legal Department, Wiley Publishing, Inc., 10475 Crosspoint Blvd., Indianapolis, IN 46256, 317-572-3447, fax 317-572-4355, or online at http:// www.wiley.com/go/permissions. Trademarks: Wiley, the Wiley Publishing logo, For Dummies, the Dummies Man logo, A Reference for the Rest of Us!, The Dummies Way, Dummies Daily, The Fun and Easy Way, Dummies.com, and related trade dress are trademarks or registered trademarks of John Wiley & Sons, Inc., and/or its affiliates in the United States and other countries, and may not be used without written permission.
    [Show full text]
  • The Prevalence of and Attitudes Toward Oligomenorrhea and Amenorrhea in Division I Female Athletes
    POPULATION-SPECIFIC CONCERNS The Prevalence of and Attitudes Toward Oligomenorrhea and Amenorrhea in Division I Female Athletes Karen Myrick, DNP, APRN, FNP-BC, Richard Feinn, PhD, and Meaghan Harkins, MS, BSN, RN • Quinnipiac University Research has demonstrated that amenor- hormone and follicle-stimulating hormone rhea and oligomenorrhea may be common shut down stimulation to the ovary, ceasing occurrences among female athletes.1 Due production of estradiol.2 to normalization of menstrual dysfunction The effect of oral contraceptives on the within the sport environment, amenorrhea menstrual cycle include ovulation inhibi- and oligomenorrhea tion, changes in cervical mucus, thinning may be underreported. of the uterine endometrium, and motility Key PointsPoints There are many underly- and secretion in the fallopian tubes, which Lean sport athletes are more likely to per- ing causes of menstrual decrease the likelihood of conception and 3 ceive missed menstrual cycles as normal. dysfunction. However, implantation. Oral contraceptives contain a a similar hypothalamic combination of estrogen and progesterone, Menstrual dysfunction is one prong of the amenorrhea profile is or progesterone only; thus, oral contracep- female athlete triad. frequently seen in ath- tives do not stop the production of estrogen. letes, and hypothalamic Menstrual dysfunction is one prong of the Menstrual dysfunction is often associated dysfunction is com- female athlete triad (triad). The triad is a with musculoskeletal and endothelial monly the root of ath- syndrome of linking low energy availability compromise. lete’s menstrual abnor- (EA) with or without disordered eating, men- malities.2 The common strual disturbances, and low bone mineral Education and awareness of the accultur- hormone pattern for density, across a continuum.
    [Show full text]
  • Prevalence of Menstrual Irregularities in Correlation with Body Fat Among Students of Selected Colleges in a District of Tamil Nadu, India
    National Journal of Physiology, Pharmacy and Pharmacology RESEARCH ARTICLE Prevalence of menstrual irregularities in correlation with body fat among students of selected colleges in a district of Tamil Nadu, India Sherly Deborah G1, Siva Priya D V2, Rama Swamy C2 1Department of Physiology, Faculty of Medicine, AIMST University, Bedong, Kedah, Malaysia, 2Department of Physiology, Saveetha Medical College, Chennai, Tamil Nadu, India Correspondence to: Sherly Deborah G, E-mail: [email protected] Received: March 05, 2017; Accepted: March 22, 2017 ABSTRACT Background: Menstrual irregularities are usually due to imbalance of hormones. Although menstrual irregularities may be normal during the early postmenarchal years, pathological conditions require proper and prompt management. Obesity associated with many health consequences including hormonal imbalance has a direct effect on menstrual cycle. Hence, attention to obesity is obligatory for the inclusion of diagnosis and treatment of menstrual complaints which has become a leading issue in women’s life. Aims and Objectives: The aims and objectives of the study are to assess the menstrual irregularities and to find the association between menstrual irregularities and body fat among students. Materials and Methods: A cross-sectional study was conducted in three selected colleges in a district of Tamil Nadu in India. A total of 399 samples were included in the study. A 10-item questionnaire was administered to assess the menstrual irregularity in each student. The demographic variables along with anthropometric measurements were collected. Anthropometric measurements were taken to calculate the body fat percentage using modified YMCA formula. Results: The prevalence of menstrual irregularities was high in obesity compared with those with normal body fat and particularly oligomenorrhea, amenorrhea, and hypomenorrhea had statistically significant increase in obese students.
    [Show full text]
  • Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
    Published OnlineFirst November 15, 2017; DOI: 10.1158/1055-9965.EPI-17-0655 Research Article Cancer Epidemiology, Biomarkers Polycystic Ovary Syndrome, Oligomenorrhea, and & Prevention Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium Holly R. Harris1, Ana Babic2, Penelope M. Webb3,4, Christina M. Nagle3, Susan J. Jordan3,5, on behalf of the Australian Ovarian Cancer Study Group4; Harvey A. Risch6, Mary Anne Rossing1,7, Jennifer A. Doherty8, Marc T.Goodman9,10, Francesmary Modugno11, Roberta B. Ness12, Kirsten B. Moysich13, Susanne K. Kjær14,15, Estrid Høgdall14,16, Allan Jensen14, Joellen M. Schildkraut17, Andrew Berchuck18, Daniel W. Cramer19,20, Elisa V. Bandera21, Nicolas Wentzensen22, Joanne Kotsopoulos23, Steven A. Narod23, † Catherine M. Phelan24, , John R. McLaughlin25, Hoda Anton-Culver26, Argyrios Ziogas26, Celeste L. Pearce27,28, Anna H. Wu28, and Kathryn L. Terry19,20, on behalf of the Ovarian Cancer Association Consortium Abstract Background: Polycystic ovary syndrome (PCOS), and one of its cancer was also observed among women who reported irregular distinguishing characteristics, oligomenorrhea, have both been menstrual cycles compared with women with regular cycles (OR ¼ associated with ovarian cancer risk in some but not all studies. 0.83; 95% CI ¼ 0.76–0.89). No significant association was However, these associations have been rarely examined by observed between self-reported PCOS and invasive ovarian cancer ovarian cancer histotypes, which may explain the lack of clear risk (OR ¼ 0.87; 95% CI ¼ 0.65–1.15). There was a decreased risk associations reported in previous studies. of all individual invasive histotypes for women with menstrual Methods: We analyzed data from 14 case–control studies cycle length >35 days, but no association with serous borderline including 16,594 women with invasive ovarian cancer (n ¼ tumors (Pheterogeneity ¼ 0.006).
    [Show full text]
  • Consensus Statement
    CONSENSUS STATEMENT ISUOG Consensus Statement on rationalization of gynecological ultrasound services in context of SARS-CoV-2 INTRODUCTION Given the challenges of the current coronavirus (SARS-CoV-2) pandemic and to protect both patients and ultrasound providers (physicians, sonographers, allied professionals), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) has compiled the following expert-opinion-based guidance for the rationalization of ultrasound investigations for gynecological indications. While the provision of ultrasound is an essential service and all individuals with gynecological complaints deserve high-quality investigation, the current coronavirus disease 2019 (COVID-19) pandemic warrants triaging of referrals for gynecological ultrasound assessment. This is based on the following principles related to a pandemic: 1. Medical resources should be spared and prioritized. 2. Maximum care should be taken to avoid unnecessary contact between (potentially infected) medical personnel and (potentially infected) patients. The risk of transmission is particularly high during ultrasound investigations as neither the medical personnel nor the patient can abide by the social distancing recommendations. 3. Visits should be limited to those strictly necessary to avoid spread of the virus. Therefore, ultrasound appointments for gynecological indications should be triaged based on the clinical scenario, as follows: 1. Ultrasound assessments that should be performed without delay (NOW); 2. Ultrasound assessments
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • LNG-IUS) in Patients Affected by Menometrorrhagia, Dysmenorrhea and Adenomimyois: Clinical and Ultrasonographic Reports
    European Review for Medical and Pharmacological Sciences 2021; 25: 3432-3439 The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports F. COSTANZI, M.P. DE MARCO, C. COLOMBRINO, M. CIANCIA, F. TORCIA, I. RUSCITO, F. BELLATI, A. FREGA, G. COZZA, D. CASERTA Department of Surgical and Medical Sciences and Translational Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, Italy Abstract. – OBJECTIVE: Adenomyosis is p=0.025; p=0.014). The blood loss decreased the consequence of the myometrial invasion significantly in both the cohorts (p<0.001) and by endometrial glands and stroma. Transvag- particularly in adenomyotic patients. Pain relief inal ultrasonography plays a decisive role in was observed in all the patients (p<0.001). the diagnosis and monitoring of this patholo- CONCLUSIONS: LNG-IUS can be considered gy. Our study aims to evaluate the efficacy of an effective treatment for managing symptoms LNG-IUS (Levonorgestrel Releasing Intrauter- and improving uterine morphology. ine System) as medical therapy. We analyzed both clinical symptoms and ultrasonograph- Key Words: ic aspects of menometrorrhagia and dysmen- Benign disease of uterus, Dysmenorrhea, Gyne- orrhea in patients with adenomyosis and the cologic imaging, Leiomyomas of the uterus/adeno- control group. myosis. PATIENTS AND METHODS: A prospective co- hort study was carried out on 28 patients suf- fering from symptomatic adenomyosis treat- ed with LNG-IUS. Adenomyosis was diagnosed Introduction through transvaginal ultrasonography by an ex- pert sonographer. A control group of 27 symp- Adenomyosis is a benign gynecological dis- tomatic patients (menorrhagia and dysmenor- ease with a large variety of clinical manifestation; rhea) without a transvaginal ultrasonograph- the most frequent include menorrhagia, metror- ic diagnosis of adenomyosis was treated in the rhagia, dysmenorrhea and chronic pelvic pain1.
    [Show full text]
  • Jceme114.Pdf
    JCEM ONLINE Brief Report—Endocrine Research Menstrual Irregularity and Cardiovascular Mortality Erica T. Wang, Piera M. Cirillo, Eric Vittinghoff, Kirsten Bibbins-Domingo, Barbara A. Cohn, and Marcelle I. Cedars Center for Research on Women’s and Children’s Health, Public Health Institute, University of California San Francisco, San Francisco, California 94115 Downloaded from https://academic.oup.com/jcem/article/96/1/E114/2833816 by guest on 29 September 2021 Background: Polycystic ovary syndrome, the most common cause of irregular menstrual cycles, is associated with an adverse cardiovascular risk profile. However, there are limited prospective studies confirming the link between polycystic ovary syndrome and cardiovascular mortality. Methods: We studied 15,005 pregnant women recruited from the Kaiser Foundation Health Plan in California between 1959 and 1966. The menstrual cycle pattern was assessed at baseline ac- cording to self-report, physician report, and medical record abstraction. Participants were matched to California Vital Status files annually until 2007 to identify deaths due to overall cardiovascular disease (CVD) and subsets of coronary heart disease (CHD) and cerebrovascular disease based on International Classification of Diseases codes. Cox proportional hazards models were used to es- timate the association between irregular cycles and cardiovascular mortality. Missing covariate data were multiply imputated using standard methods. Results: During 456,298.5 person-years of follow-up, there were 666 CVD deaths, including 301 CHD deaths and 149 cerebrovascular deaths. Compared with women with regular cycles, women with irregular cycles had an increased risk for CHD mortality [age adjusted hazards ratio (HR) 1.42, 95% confidence interval (CI) 1.03–1.94]; however, the association was not statistically significant after adjustment for body mass index (adjusted HR 1.35, 95% CI 0.98–1.85).
    [Show full text]
  • American Family Physician Web Site At
    Diagnosis and Management of Adnexal Masses VANESSA GIVENS, MD; GREGG MITCHELL, MD; CAROLYN HARRAWAY-SMITH, MD; AVINASH REDDY, MD; and DAVID L. MANESS, DO, MSS, University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee Adnexal masses represent a spectrum of conditions from gynecologic and nongynecologic sources. They may be benign or malignant. The initial detection and evaluation of an adnexal mass requires a high index of suspicion, a thorough history and physical examination, and careful attention to subtle historical clues. Timely, appropriate labo- ratory and radiographic studies are required. The most common symptoms reported by women with ovarian cancer are pelvic or abdominal pain; increased abdominal size; bloating; urinary urgency, frequency, or incontinence; early satiety; difficulty eating; and weight loss. These vague symptoms are present for months in up to 93 percent of patients with ovarian cancer. Any of these symptoms occurring daily for more than two weeks, or with failure to respond to appropriate therapy warrant further evaluation. Transvaginal ultrasonography remains the standard for evaluation of adnexal masses. Findings suggestive of malignancy in an adnexal mass include a solid component, thick septations (greater than 2 to 3 mm), bilaterality, Doppler flow to the solid component of the mass, and presence of ascites. Fam- ily physicians can manage many nonmalignant adnexal masses; however, prepubescent girls and postmenopausal women with an adnexal mass should be referred to a gynecologist or gynecologic oncologist for further treatment. All women, regardless of menopausal status, should be referred if they have evidence of metastatic disease, ascites, a complex mass, an adnexal mass greater than 10 cm, or any mass that persists longer than 12 weeks.
    [Show full text]
  • Association Between Menstrual Disorders and Obesity
    ArchiveInt J School of Health SID. 2018 April; 5(2):e65716. doi: 10.5812/intjsh.65716. Published online 2018 April 17. Research Article Association Between Menstrual Disorders and Obesity-Related Anthropometric Indices in Female High School Students: A Cross-Sectional Study Mostafa Rad,1 Marzieh Torkmannejad Sabzevary,2 and Zahra Mohebbi Dehnavi3,* 1Faculty of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, IR Iran 2Mobini Hospital, Sabzevar University of Medical Sciences, Sabzevar, IR Iran 3Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, IR Iran *Corresponding author: Zahra Mohebbi Dehnavi, Department of Midwifery and Reproductive Health, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, IR Iran. Tel: +98-9139752086, E-mail: [email protected] Received 2018 January 02; Revised 2018 April 11; Accepted 2018 April 13. Abstract Background: The menstrual cycle determines the health of women. Menstrual disorders are a major Geneologic problem among women, especially adolescents, which is a major source of anxiety for them and their families. Factors such as BMI, exercise, and stress can be related to menstrual disorders. As a result, this study was conducted to determine the association between menstrual disorders and anthropometric indices in Female High School Students. Methods: This descriptive cross-sectional study was conducted in Sabzevar on 200 high school female students in 2017. The partici- pants first completed the personal, midwifery,
    [Show full text]